Evidence map›Paper›PMID 34096630›Full record

ArticleBritish journal of haematology2021

Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.

Jason Ostergaard, Leslie M Jonart, Maryam Ebadi, Stacia L Koppenhafer, David J Gordon, Peter M Gordon

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. American journal of translational research · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jason OstergaardDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN, USA.
Leslie M JonartDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN, USA.
Maryam EbadiDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-9452-1488
Stacia L KoppenhaferDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Iowa City, IA, USA.
David J GordonDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Iowa City, IA, USA.ORCID 0000-0003-1830-4371
Peter M GordonDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-3159-1881

Funding

Gene Expression Signature Based Screening in Ewing SarcomaR37CA217910 · NCI · UNIVERSITY OF IOWA · PI GORDON, DAVID J · 2018 to 2024
$2.6M
Overcoming Leukemia Chemoresistance in the Central Nervous SystemR37CA240846 · NCI · UNIVERSITY OF MINNESOTA · PI PETER M GORDON · 2020 to 2026
$2.4M
NCI NIH HHS R37 CA217910NCI NIH HHS R37 CA240846
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsCell Line, TumorCell ProliferationCheckpoint Kinase 1DeoxycytidineDrug SynergismGemcitabineHumansMicePrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsPyrazinesPyrazolesCheckpoint Kinase 1DeoxycytidineGemcitabineprexasertibProtein Kinase InhibitorsPyrazinesPyrazoles

Identifiers

PMID34096630
PMCPMC8504167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.